Will dabrafenib targeted drug be included in medical insurance?

Dabrafenib (Dabrafenib) is a targeted drug mainly used to treat cancers with BRAF V600E/V600K/V600D mutations. Dabrafenib is a small molecule tyrosine kinase inhibitor (TKI) that binds to the protein product encoded by the mutated BRAF gene, thereby exerting a tumor suppressor effect.

Dabrafenib's approved indications at home and abroad mainly include advanced melanoma with BRAF V600E/V600K mutations, metastatic non-small cell lung cancer, and locally advanced or metastatic anaplastic thyroid cancer.

In clinical studies, dabrafenib combined with trametinib treatment can significantly extend the median overall survival of patients compared with dabrafenib monotherapy. For example, in patients with advanced melanoma, combination therapy can achieve a 5-year survival rate of 34%.

In conclusion, dabrafenib, as an effective targeted drug, plays an important role in cancer treatment targeting specific mutations.

In my country, dabrafenib has been successfully sold and covered by medical insurance policies, which undoubtedly brings good news to patients. Currently, the original drug of dabrafenib available in the domestic market has two packaging options:75mg 120 tablets and 50mg 120 tablets. With the support of medical insurance, the price of 75 mg dabrafenib has dropped to about 12,000 yuan. At the same time, the drug has also attracted widespread attention in the international market, with both original and generic versions. It is worth mentioning that the price of the 75mg 120-capsule original drug produced by Novartis in the Turkish market is 11,000 yuan per box. Several generic versions of dabrafenib are available in a unified specification of 75mg and 120 tablets, with the price remaining at about 2,700 yuan.